Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
Source: finance.yahoo.com
Related posts:
Apple Earnings Are Next. Back the Stock for This Reason, Analyst Says.
Private Equity Team at $76 Billion Pension Hit by Wave of Exits
Former Microsoft CEO Steve Ballmer is on pace to earn $1 billion in dividends annually from his mass...
Consumer Spending Could Spell Trouble for the Economy
U.N. Calls On Fed, Other Central Banks to Halt Interest-Rate Increases